Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anti-CXCR4 (BMS-936564)
Anti-CXCR4 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm A: Anti-CXCR4 (BMS-936564)+Lenalidomide+Dexamethasone | EXPERIMENTAL | - |
| Arm B: Anti-CXCR4 (BMS-936564)+Bortezomib+Dexamethasone | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Anti-CXCR4 (BMS-936564) | BIOLOGICAL | Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles |
| Lenalidomide | BIOLOGICAL | Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21 |
| Dexamethasone | BIOLOGICAL | Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles |
| Bortezomib | BIOLOGICAL | Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11 |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Subjects must have confirmed diagnosis of multiple myeloma with measurable disease Excluded are subjects with only plasmacytomas, plasma cell leukemia, or non-secretory myel...
Top 20 of 25 competitors
Anti-CXCR4 is an investigational monoclonal antibody being studied for the treatment of multiple myeloma, a cancer of plasma cells in the bone marrow. It was evaluated in patients with relapsed or refractory multiple myeloma, both as a single agent and in combination with other therapies. It is not approved for any indication.
Anti-CXCR4 targets the CXCR4 receptor, a chemokine receptor that is a monoclonal antibody. By binding to CXCR4, the drug is designed to block signaling through this receptor, which is involved in the trafficking and retention of myeloma cells in the bone marrow microenvironment.
Anti-CXCR4 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company sponsored the clinical trial that evaluated the drug in multiple myeloma.
Anti-CXCR4 is in Phase 1 clinical development. It has completed one Phase 1 trial in relapsed or refractory multiple myeloma. The drug remains investigational and has not been approved by the FDA for any indication.
Anti-CXCR4 has been studied in one completed Phase 1 trial, NCT01359657, titled Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma. The trial enrolled 46 patients in the United States and is no longer active.
Yes, Anti-CXCR4 is also known as BMS-936564. The two names refer to the same investigational monoclonal antibody developed by Bristol-Myers Squibb. BMS-936564 is the company's internal designation for the anti-CXCR4 antibody.